Insights

Growth Recognition AKESOgen has been recognized as an Inc. 500 fastest-growing firm, signaling strong market momentum and potential for upsell opportunities with larger clients and new government programs.

Large-Scale Partnerships Historically engaged in high-impact collaborations (e.g., VA Million Veteran Program, RenalytixAI, Cytox, Nutrisystem) suggests demand for wide-scale biomarker profiling, pharmacogenomics, and precision medicine services across pharma, nutrition, and AI-enabled healthcare sectors.

Clinical Trial Focus Expertise in establishing and validating biomarkers for clinical trials positions AKESOgen as a partner for sponsors needing biomarker strategies, patient stratification, and companion diagnostics to accelerate trial timelines.

Genomics Capabilities Capabilities in next-generation sequencing, genotyping, and multiple markers (DNA, RNA, miRNA, methylation) align with opportunities to offer end-to-end genomics services to academic, biotech, and agricultural customers seeking comprehensive data generation and analysis.

Biobanking & Compliance Strength in biobanking and ISO-aligned operations provides a selling point for customers requiring robust sample management, data integrity, and regulatory compliance in multi-site or multi-study programs.

Similar companies to AKESOgen, Inc.

AKESOgen, Inc. Tech Stack

AKESOgen, Inc. uses 8 technology products and services including ISO, WordPress, Google Fonts API, and more. Explore AKESOgen, Inc.'s tech stack below.

  • ISO
    Certificates
  • Content Management System
  • Google Fonts API
    Font Scripts
  • jQuery
    Javascript Libraries
  • Microsoft Word
    Office Suites
  • C#
    Programming Languages
  • JSON
    Programming Languages
  • YouTube
    Video Players

Media & News

AKESOgen, Inc.'s Email Address Formats

AKESOgen, Inc. uses at least 3 email formats:
AKESOgen, Inc. Email FormatsExamplePercentage
FLast@akesogen.comJDoe@akesogen.com
93%
Last_First@akesogen.comDoe_John@akesogen.com
5%
FirstLas@akesogen.comJohnDoe@akesogen.com
2%

Frequently Asked Questions

What is AKESOgen, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact AKESOgen, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is AKESOgen, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
AKESOgen, Inc.'s official website is akesogen.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does AKESOgen, Inc. generate?

Minus sign iconPlus sign icon
As of July 2026, AKESOgen, Inc.'s annual revenue is estimated to be $1M - $10M.

What is AKESOgen, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
AKESOgen, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AKESOgen, Inc. have currently?

Minus sign iconPlus sign icon
As of July 2026, AKESOgen, Inc. has approximately 51 employees across 1 continents, including North America. Key team members include Assistant Project Manager: D. H., Human Resources Manager: J. H. and Project Coordinator: J. M. Explore AKESOgen, Inc.'s employee directory with LeadIQ.

What industry does AKESOgen, Inc. belong to?

Minus sign iconPlus sign icon
AKESOgen, Inc. operates in the Biotechnology Research industry.

What technology does AKESOgen, Inc. use?

Minus sign iconPlus sign icon
AKESOgen, Inc.'s tech stack includes ISO, WordPress, Google Fonts API, jQuery, Microsoft Word, C#, JSON and YouTube.

What is AKESOgen, Inc.'s email format?

Minus sign iconPlus sign icon
AKESOgen, Inc.'s email format typically follows the pattern of FLast@akesogen.com. Find more AKESOgen, Inc. email formats with LeadIQ.

How much funding has AKESOgen, Inc. raised to date?

Minus sign iconPlus sign icon
As of July 2026, AKESOgen, Inc. has raised $1.9M in funding. The last funding round occurred on Apr 03, 2019 for $1.5M.

When was AKESOgen, Inc. founded?

Minus sign iconPlus sign icon
AKESOgen, Inc. was founded in 2010.
AKESOgen, Inc. logo

AKESOgen, Inc.

Biotechnology ResearchGeorgia, United States51-200 Employees

AKESOgen, Inc. is a biotechnology research organization that acts as a contract research organization focused on biomarker discovery, genomics, and pharmacogenomics. It serves academic, pharmaceutical, biotechnology, and agricultural clients by providing biomarker profiling and genomics services, including sequencing and genotyping across multiple molecular markers to support research and development efforts. The company also specializes in establishing and validating biomarkers for clinical trials and has expertise in biobanking, enabling researchers to manage and utilize biological samples for studies. Based in the Atlanta area, AKESOgen operates within the broader biotechnologies and precision medicine landscape, offering services to projects that require analysis of DNA, RNA, and other molecular markers. The firm has engaged in collaborations with industry partners, including notable partnerships and acquisitions reported in recent years. AKESOgen is headquartered in Norcross, Georgia, and has a workforce that positions it within the mid-sized segment of the sector. } }{

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
51-200

Section iconFunding & Financials

  • $1.9M

    AKESOgen, Inc. has raised a total of $1.9M of funding over 5 rounds. Their latest funding round was raised on Apr 03, 2019 in the amount of $1.5M as a Venture Round.

  • $1M - $10M

    AKESOgen, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.